Azenta (AZTA) Stock Price, News & Analysis

Company Overview

Azenta, Inc. (NASDAQ: AZTA) is a life sciences company that provides solutions for the management, storage, and analysis of biological samples. Its customers include pharmaceutical and biotechnology companies, academic and government research institutions, clinical research organizations, and other organizations involved in drug discovery, clinical research, and genomic analysis.

The company offers automated sample-management systems, ultra-low-temperature and cryogenic storage equipment, laboratory automation, consumables, and software for tracking and managing biological specimens. Azenta also provides sample logistics and related services designed to support the secure movement and long-term preservation of biological materials.

Through its GENEWIZ business, Azenta provides genomic services such as DNA sequencing, gene synthesis, and other sequencing and bioinformatics solutions. The company serves customers internationally through operations and service capabilities in North America, Europe, and Asia.

Azenta was previously known as Brooks Automation, Inc. and adopted its current name after separating its semiconductor-solutions business to focus on life sciences. The company is headquartered in Chelmsford, Massachusetts.

Key Stats

• Today's Range: $33.03 to $33.82
• 50-Day Range: $25.44 to $37.40
• 52-Week Range: $15.93 to $41.73
• Volume: 1.43 million shs
• Average Volume: 802,358 shs
• Market Capitalization: $1.46 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $41.20
• Consensus Rating: Hold

Azenta Stock Analysis - MarketRank™

Azenta scored higher than 49% of companies evaluated by MarketBeat, and ranked 593rd out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

Azenta has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Azenta has a consensus price target of $41.20, representing about 23.9% upside from its current price of $33.24.

Amount of Analyst Coverage

Azenta has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Azenta is -12.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Azenta is -12.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Azenta has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.76% of the float of Azenta has been sold short.

Short Interest Ratio / Days to Cover

Azenta has a short interest ratio ("days to cover") of 7.14.

Change versus previous month

Short interest in Azenta has recently increased by 2.29%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Azenta does not currently pay a dividend.

Dividend Growth

Azenta does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.39

News Sentiment

Azenta has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Azenta this week, compared to 3 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Azenta insiders have bought more of their company's stock than they have sold. Specifically, they have bought $8,097.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

10.90% of the stock of Azenta is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

99.08% of the stock of Azenta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 9/19/2026
• Fiscal Year End: 9/30/2026
• Next Earnings (Estimated): 11/20/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:AZTA
• CIK: 933974
• Web: www.azenta.com
• Phone: (978) 262-2400
• Fax: 978-262-2500
• Employees: 3,000
• Year Founded: 1978

Price Target and Rating

• Average Price Target for Azenta: $41.20
• High Price Target: $45.00
• Low Price Target: $37.00
• Potential Upside/Downside: +23.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$55.76 million
• Net Margins: -20.63%
• Pretax Margin: -24.81%
• Return on Equity: 1.18%
• Return on Assets: 0.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.50
• Quick Ratio: 2.21

Sales & Book Value

• Annual Sales: $593.82 million
• Price / Sales: 2.45
• Cash Flow: $1.79 per share
• Price / Cash Flow: 18.56
• Book Value: $37.67 per share
• Price / Book: 0.88

Miscellaneous

• Outstanding Shares: 43,810,000
• Free Float: 39,033,000
• Market Cap: $1.46 billion
• Optionable: Optionable
• Beta: 1.39